With over 4,400 confirmed measles cases and 42 outbreaks reported in the U.S. in 2026, the resurgence is raising serious concerns for a particularly vulnerable group: immunosuppressed patients. For those on biologics, JAK inhibitors, or high-dose steroids — often treating conditions like psoriasis, atopic dermatitis, or lupus — measles can look very different and hit much harder.

Unlike healthy individuals, immunocompromised patients may not develop the hallmark head-to-toe rash, making diagnosis trickier. Standard serology tests can also be unreliable in this population, meaning clinicians need to rely on PCR testing via throat swabs or blood samples. Serious complications — including pneumonia, encephalitis, liver failure, and death — are significantly more likely in these patients.

Key Takeaways:

• The MMR vaccine is contraindicated for patients on high-dose steroids and generally avoided in those on biologics or JAK inhibitors
• Post-exposure prophylaxis options include the MMR vaccine (within 72 hours) or immunoglobulins (within 6 days) — but never both, as they interfere with each other
• Ideally, vaccination should occur before starting immunosuppressive therapy; if already on treatment, stopping for 2–3 drug half-lives may be needed before vaccinating

Why it matters: As measles outbreaks spread across multiple states, clinicians managing immunosuppressed patients must proactively counsel on risk, revisit vaccination history, and know when and how to act fast after exposure.